<unk>  management of pulmonic<unk>  may include pulmonary valve replacement (PVR). The major indications for PVR may include symptomatic patients with arrythmias or NYHA class higher than II, an ejection fraction of less than 40% when assessed with CMR, patients with progressive right ventricular<unk> (right ventricular end- diastolic volume ≥160 mL/m2 or end-systolic volume ≥82 mL/m2 on CMR), moderate to severe tricuspid valve<unk> , resulting from annular dilatation, patients at risk of developing arrythmias and with prolonged QRS duration.(total QRS duration ≥180 msec, or QRS duration increase >3.5 msec per year and severe pulmonic<unk>  among patients with another cardiac lesion that requires operative intervention. Timing of pulmonary valve replacement is not well defined. However timely intervention is advised before the onset of RV dysfunction. Pulmonary valve replacement (PVR) by<unk>  and percutaneous approach is the definitive treatment for the management of chronic PR and has proven to improve RV function, New York Heart Association Functional Class status, quality of life, and reduce risk for development of RV tachyarrhythmias and sudden cardiac death. Among patients with arrhythmias, intraoperative electrophysiological mapping with cryoablation during pulmonary valve replacement has demonstrated promising results.
Pulmonary regurgitation surgical therapy
Pulmonary regurgitation medical therapy
Pulmonic regurgitation medical therapy
Pulmonic regurgitation treatment
Tricuspid stenosis medical therapy
Chronic mitral regurgitation treatment
Arrhythmogenic right ventricular dysplasia medical therapy
Bicuspid aortic stenosis treatment